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Abstract
Introduction: Female sex workers (FSW) who use drugs are a key population at risk of HIV in Kazakhstan, and face multiple
structural barriers to HIV prevention. More research is needed on the role of structural interventions such as microfinance
(MF) in reducing HIV risk. This paper describes the results of a cluster-randomized controlled trial to test the efficacy of a
combination HIVRR + MF intervention in reducing biologically confirmed STIs and HIV risk behaviours.
Methods: This study took place from May 2015 to October 2018 in two cities in Kazakhstan. We screened 763 participants
for eligibility and enrolled 354 FSW who use drugs. Participants were randomized in cohorts to receive either a four-session
HIVRR intervention, or that same intervention plus 30 additional sessions of financial literacy training, vocational training and
asset-building through a matched-savings programme. Repeated behavioural and biological assessments were conducted at
baseline, 3-, 6- and 12-months post-intervention. Biological and behavioural primary outcomes included HIV/STI incidence, sex-
ual risk behaviours and drug use risk behaviours, evaluated over the 12-month period.
Results: Over the 12-month follow-up period, few differences in study outcomes were noted between arms. There was only
one newly-detected HIV case, and study arms did not significantly differ on any STI incidence. At post-intervention assess-
ments compared to baseline, both HIVRR and HIVRR + MF participants significantly reduced sexual and drug use risk beha-
viours, and showed improvements in financial outcomes, condom use attitudes and self-efficacy, social support, and access to
medical care. In addition, HIVRR + MF participants showed a 72% greater reduction in the number of unprotected sex acts
with paying partners at the six-month assessment (IRR = IRR = 0.28, 95% CI = 0.08, 0.92), and a 10% greater reduction in
the proportion of income from sex work at the three-month assessment (b = 0.10, 95% CI = 0.17, 0.02) than HIVRR
participants did. HIVRR + MF participants also showed significantly improved performance on financial self-efficacy compared
to HIVRR over the 12-month follow-up period.
Conclusions: Compared to a combination HIVRR + MF intervention, a robust HIVRR intervention alone may be sufficient to
reduce sexual and drug risk behaviours among FSW who use drugs. There may be structural limitations to the promise of
microfinance for HIV risk reduction among this population.
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1 | INTRODUCTION
Female sex workers (FSW) are a key population at high risk
for HIV and other sexually transmitted infections (STIs). In low
and middle-income countries, estimates put their odds of HIV
infection at 13.5 times those of all women of reproductive
age [1]. While injection drug use has historically driven the
HIV epidemic in Central Asia, there is growing attention to
the role of FSW [2]. Kazakhstan has an estimated 21,450
FSW, 1.4% of whom are HIV positive [3]. An estimated 2.3%
of Kazakhstan’s FSW inject drugs; there are no estimates of
non-injection drug use among FSW [3]. There is a lack of
structural HIV prevention interventions among women who
use drugs, part of a larger trend of women’s underrepresenta-
tion in substance use research [4,5]. Some evidence suggests
that HIV burden may be even higher among FSW who use
injection or non-injection drugs [2]. While often considered
distinct populations, FSW who are also injection or non-injec-
tion drug users face overlapping physical, social, economic and
policy risk environments that may limit their ability to
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negotiate safe sex, practice safe injection, protect themselves
from violence from clients, managers, or intimate partners, or
seek necessary medical or social services [6,7]. Substance use
may drive entry into sex work, and may exacerbate risks faced
by FSW, reducing their capacity to insist on client condom use
and increasing their experience of violence, including by police
[7]. These structural barriers also limit access to treatment
and care.
Structural interventions such as microfinance have the
potential to address the economic risk environment faced by
FSW who use drugs. The promise of microfinance for HIV risk
reduction has received much interest, though few empirical
results [8]. Microfinance interventions for HIVRR can take
many forms – reviews have highlighted a range of programmes,
including financial-literacy education, vocational training, condi-
tional or unconditional cash transfers, formal or informal micro-
credit or lending, small-business development and asset-
building through savings programmes [9-11]. Few microfinance
studies have been conducted among FSW, and only one among
FSW who use drugs. The results suggest that among FSW,
receiving a microfinance intervention may be associated with a
reduced number of paying partners [12-15], increased condom
use [12,14,15] and alternative income [13,15]. They suggest
that providing women with increased economic opportunities
decreases their reliance on sex work and high-risk unprotected
sex for income. However, existing studies insufficiently address
empirical concerns, as one lacked a controlled design and none
included biological outcome measures.
The Nova study addresses these gaps by rigorous evalua-
tion of a combination HIV Risk Reduction (HIVRR) and micro-
finance (MF) intervention among FSW who used drugs in
Kazakhstan. We hypothesized that compared to those who
received the HIVRR intervention alone, participants who
received a combination HIVRR + MF intervention would see
(1) lower cumulative incidence of biologically confirmed STIs
(gonorrhoea, trichomoniasis, chlamydia), (2) lower rate of new
HIV cases, (3) greater decrease in the number of unprotected
vaginal and anal sexual acts and a greater increase in the pro-
portion of protected sexual acts with both intimate and paying
partners, (4) reduction in the proportion of unsafe injection
acts for those participants who inject drugs, and (5) lower
proportion of monthly income from sex work.
2 | METHODS
This study utilized a cluster-randomized controlled trial (cRCT)
design to compare participants receiving HIVRR alone and
participants receiving HIVRR + MF. Recruitment and enrol-
ment began in May 2015, and follow-up data collection ended
in October 2018. All procedures received approval from the
Institutional Review Board (IRB) at Columbia University and
the Ethics Committee of the Kazakhstan School of Public
Health.
2.1 | Recruitment of participants
The study took place in Almaty and Temirtau, two cities in
Kazakhstan. Information on these cities is available elsewhere
[16]. We recruited participants from NGOs, medical and social
service organizations, and peer referrals. Research assistants
distributed informational brochures and conducted outreach
to provide study information to potential participants.
2.2 | Screening for eligibility
Research assistants administered a brief computer-based eligi-
bility screening. Participants were eligible if they reported: (a)
being over 18 years old; (b) illicit drug use within the past
12 months; (c) having exchanged sex for money, goods, drugs,
or services within the past 90 days and (d) at least one inci-
dence of unprotected sex (with either a paying or non-paying
partner) within the past 90 days. Participants were ineligible if
they (a) could not communicate in Russian; (b) intended to
move from the study site within the next year or (c) were
determined to have cognitive impairment that would affect
their ability to provide consent or participate fully. Participants
received $1 for screening completion.
2.3 | Study procedures
2.3.1 | Randomization
Eligible participants completed an informed consent process
at a Nova field office, followed by a baseline assessment (see
below). Within two weeks of baseline, participants were
enrolled into 53 cohorts of six to eight participants. We ran-
domized each cohort to either the treatment (HIVRR + MF)
or control (HIVRR only) arm of the study through the use of a
random number generator, conducted by the study biostatisti-
cian. Neither participants nor study staff were blind to study
arm assignment.
2.3.2 | Intervention
Detailed information on intervention components, intervention
selection, and adaptation is provided elsewhere [17]. Both
arms received four HIVRR sessions. Participants assigned to
the combination HIVRR + MF treatment arm received 30
additional sessions, including (1) six financial literacy training
sessions, (2) 24 vocational training sessions in hairdressing,
sewing, or manicurist professions and (3) a matched-savings
programme incentivizing them to accumulate assets for small-
business development or job/vocational training. Participants
received small financial incentives ($12 per session attended),
as well as small safe-sex kits of condoms and lubricant. Ses-
sions included brief safety check-ins assessing whether partici-
pants faced risks of violence related or unrelated to study
participation. Facilitators brought all expressed referral needs
to the research team, who worked to link participants to
requested services.
HIV risk reduction
Participants in both study arms received four 2-hour HIVRR
sessions, delivered by trained facilitators over two weeks.
HIVRR focused on sexual and drug use risk reduction, and
aimed to increase communication, problem-solving skills, and
self-efficacy related to safe-sex behaviours and drug use.
Financial literacy training
Only the HIVRR + MF arm received six 2-hour FLT sessions,
delivered by trained facilitators over two weeks. FLT focused
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on facilitating access to banking services, household budgeting,
short and long-term savings, and debt management.
Intervention facilitators for both components received
weekly supervision from the research team. Audio recording
and review by the research team were used for ongoing
training.
Vocational training
After completing FLT, the HIVRR + MF arm received 24 ses-
sions (two months) of Vocational Training (VT) in either hair-
dressing, sewing, or manicurist education, conducted by
community-based institutes or individuals.
Matched savings
HIVRR + MF arm participants received matched savings dur-
ing FLT and VT. For every dollar of incentive payment ($12
per session) deposited in a personal bank account, the project
deposited an equal amount in a separate, project-controlled
account under the participant’s name. Participants who saved
100% of their incentive would receive a matching $360 for a
total of $720. For up to six months following the last VT ses-
sion, participants could use this matched amount to purchase
items related to their chosen vocation or to pay for continuing
education in their vocation.
2.3.3 | Baseline and follow-up assessments
Assessments took place at pre-intervention baseline (prior to
cohort assignment and randomization), then at three, six, and
twelve months following intervention completion. Follow-up
assessments allocated equivalent time for both arms, for
example the 2.5 months for the intervention sessions (see Fig-
ure 1). Each assessment consisted of a behavioural question-
naire conducted using computer-assisted self-interviewing
(CASI) and baseline, 6, and 12 months included biological
assays for HIV and three STIs, conducted by a clinical
Figure 1. CONSORT flow diagram.
El-Bassel N et al. Journal of the International AIDS Society 2021, 24:e25682
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25682/full | https://doi.org/10.1002/jia2.25682
3
coordinator in each field office. Participants received the
equivalent of US $10, $9, $11, and $16 for completion of
baseline, 3-month, 6-month, and 12-month follow-up assess-
ments respectively.
Outcomes
Aligned with our study hypotheses, our primary biological and
behavioural outcomes included:
1 Incidence of biologically confirmed STIs (gonorrhoea,
chlamydia, trichomoniasis).
2 Rate of new HIV cases.
3 Number and proportion of unprotected vaginal and anal
sex acts with both regular and paying partners.
4 Whether participant used injection drugs.
5 Whether participant performed unsafe injection.
6 Proportion of monthly income received from sex work.
Secondary outcomes included: the number of paying/non-
paying partners, condom use self-efficacy, condom use atti-
tudes, financial self-efficacy, financial safety, perceived social
support, and self-reported access to care.
Measures
A complete list of measures is available elsewhere [16].
Sociodemographic information collected included age, ethnic-
ity, marital status, education, and income.
To assess both sexual risk behaviours and drug use risk beha-
viours, we utilized a modified Risk Behaviour Assessment
(RBA) [18], including data on type and frequency of drugs
used, number of sexual partners (paying and intimate) in the
past 90 days, and sex acts and condom use with these part-
ners. We used Likert-scale measures (detailed in Table 3) to
measure attitudes towards condom use, condom use self-efficacy,
social support [19], and access to care [18].
For financial outcomes participants reported their total
income and the proportion from sex work. Participants also
completed measures of financial self-efficacy and financial safety
[20,21].
For biotesting we selected three STIs (gonorrhoea, chlamy-
dia, trichomoniasis) as proxies of sexual risk behaviour, based
on their high prevalence and incidence in FSW populations
and the availability of definitive treatment with a single-dose
medication. Clinical coordinators collected vaginal swab sam-
ples to assess these STIs, using the AmpliSens N.gonorrhoeae/
C.trachomatis/T.vaginalis-MULTIPRIME-FRT PCR assay (sensi-
tivity = 95.1%, specificity = 99.4%). We assessed HIV through
blood samples collected from participants using the Alere
DetermineTM HIV-1/2 Ag/Ab Combo rapid test system (sensi-
tivity = 100%, specificity = 98.80%). Participants who tested
positive for HIV or STIs immediately received referrals and
treatment.
2.3.4 | Statistical analysis
Power analyses suggested that a sample size of 350, random-
izing in equal proportions to each arm (175 participants each),
would achieve 80% power to detect STI incidence relative
risks equal to 0.25 comparing women randomized to
HIVRR + MF to HIVRR alone. These power analyses took into
account baseline prevalence estimates from our prior work in
similar populations [22], modest intra-class correlation coeffi-
cient equal to 0.01 for clustering effects, and 20% attrition
over the follow-up period. The details can be found in the
study protocol paper [16].
We employed statistical methods consistent with the inten-
tion-to-treat approach. For biological outcomes, we calculated
person-year incidence rates for HIV and STIs by arms. We
defined “any STI” as any new infection of gonorrhoea, chlamy-
dia or trichomoniasis detected at six or 12-month follow-up.
Poisson regressions with robust variance were used to assess
differences between arms. For self-report outcomes, we
employed mixed-effects models to estimate effects of the
change from baseline to each follow-up for both arms and to
test differences of change between two arms. Random effect
parameters for repeated measures over time were included to
handle non-independence in observations. Each mixed model
also included arm, follow-up time, the interaction between
arm and follow-up time, and covariate adjustments for age,
education, marital status, homelessness, food insecurity, and
research sites. We used mixed-effects Poisson regression to
estimate effects on the number of unprotected vaginal inter-
course acts and the number of sex partners. We reported
estimates of effects as incident rate ratios (IRR) and corre-
sponding 95% confidence intervals (CIs). We used mixed-ef-
fects logistic regression to estimate effects on injection drug
use, and reported odds ratios (OR) and 95% CIs. We
employed mixed-effects linear regression for financial out-
comes, condom use attitudes, social support, and access to
care. For these effect estimates, we report regression coeffi-
cients (b) and 95% CIs. All statistical analyses were performed
using Stata (version 15.1).
3 | RESULTS
We screened 763 individuals of whom 401 met eligibility cri-
teria and completed the baseline assessment. Of these, 354
were enrolled and randomized into either the HIVRR + MF
arm (n = 175) or the HIVRR arm (n = 179). There were no
significant differences between study arms with respect to
overall retention rates (HIVRR + MF = 92.67% vs.
HIVRR = 92.7; retention rates at each follow-up are provided
in Figure 1). Both arms had high HIVRR attendance (average
of 3.5 of 4 sessions). HIVRR + MF participants had an average
session attendance of 4.9 out of 6 and 19.6 out of 24, for FLT
and VT courses respectively. Over 75% (n = 133) of
HIVRR + MF participants were eligible for the matched sav-
ings, but only 86 (49.1%) deposited money. The average
deposit was US $149. Challenges to intervention uptake, as
well as barriers to matched-savings adherence, have been pre-
sented elsewhere [17]. Investigators identified no safety con-
cerns related to intervention participation. Table 1 describes
sociodemographic characteristics and criminal justice involve-
ment at baseline assessment for 354 participants by interven-
tion assignment. Sociodemographic characteristics and justice
involvement variables did not differ significantly between the
arms.
Table 2 reports per 100 person-year incidence rates for
HIV and STIs by arm. There was only one newly detected HIV
case with 153.3 person-years in the HIVRR arm (i.e. 0.7 per
100 person-years) over the one-year follow-up period. There
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were 41 newly detected STI cases with 130.3 person-years in
the HIVRR arm (i.e. 31.5 per 100 person-years) and 39 new
STI cases with 130.3 person-years in the HIVRR + MF arm
(i.e. 29.9 per 100 person-years). The study arms did not signif-
icantly differ on HIV, gonorrhoea, chlamydia, trichomoniasis,
and any STI incidence.
Table 3 presents descriptive statistics of both primary and
secondary behavioural outcome measures reported at the
baseline, 3, 6, and 12-month follow-up assessments by inter-
vention assignment. HIVRR + MF participants reported a sig-
nificantly lower average proportion of income from sex work
(0.15 vs. 0.23), greater average scores on financial safety
(17.1 vs. 16.4) and condom use attitudes (22.3 vs. 20.9) than
HIVRR participants at the 6-month assessment. HIVRR + MF
participants also reported greater average scores on
perceived social support at three months and 12 months
(57.8 vs. 49.9 and 57.6 vs. 51.8 respectively) and on access to
care at all assessments (17.8 vs. 16.4 at baseline, 19.1 vs.
17.7 at three months, 19.5 vs. 18.0 at six months and 20.5 vs.
18.2 at 12 months) than HIVRR participants.
Tables 4 and 5 report multilevel models to estimate quanti-
tatively the effect of change from baseline to each follow-up
assessment and the difference in this change between
HIVRR + MF vs. HIVRR on each behavioural outcome mea-
sure. Table 4 shows significant differences between arms in
the reduction from baseline to the follow-up assessment in
the number of unprotected acts of vaginal and/or anal inter-
course with paying partners and the proportion of income
from sex work. Participants assigned to HIVRR + MF reported
a 72% greater reduction in the number of unprotected acts of
Table 1. Descriptive statistics of the sample reported at the baseline assessment
Total (N = 354)a HIVRR (n = 179)a HIVRR + MF (n = 175)
Age, mean (SD) 34.0 (8.4) 34.0 (8.4) 34.1 (8.4)
Almaty site 222 (62.9%) 109 (61.2%) 113 (64.6%)
Russian 238 (67.4%) 119 (66.9%) 119 (68.0%)
Completed high school and above 239 (67.7%) 120 (67.4%) 119 (68.0%)
Single, never married 110 (31.2%) 55 (30.9%) 55 (31.4%)
Married or common law marriage 96 (27.2%) 48 (27.0%) 48 (27.4%)
Homeless in the past 90 day 204 (57.8%) 109 (61.2%) 95 (54.3%)
Not enough money to buy food in the past 90 days 319 (90.4%) 162 (91.0%) 157 (89.7%)
Years in sex work, mean (SD) 9.8 (7.3) 10.2 (7.2) 9.3 (7.3)
Ever been arrested or detained 275 (77.9%) 138 (77.5%) 137 (78.3%)
Ever been charged 178 (50.4%) 87 (48.9%) 91 (52%)
Ever been in jail or prison 111 (31.4%) 55 (30.9%) 56 (32.0%)
Been arrested or detained in the past 90 days 100 (28.3%) 53 (29.8%) 47 (26.9%)
Been charged in the past 90 days 24 (6.8%) 12 (6.7%) 12 (6.9%)
Been in jail or prison in the past 90 days 11 (3.1%) 5 (2.8%) 6 (3.4%)
HIVRR, HIV risk reduction; HIVRR + MF, HIV risk reduction and microfinance.
a
1 Missing case.








# Positive over one
year






HIV HIVRR 41 1 0 153.3 1 0.7 [0.1, 4.6]
HIVRR + MF 40 0 0 153.3 0 0 [–, –]
Gonorrhoea HIVRR 5 2 1 153 3 2.0 [0.6, 6.1]
HIVRR + MF 3 4 0 150.5 4 2.7 [1.0, 7.1]
Chlamydia HIVRR 21 9 9 147 15 10.2 [6.2, 16.9]
HIVRR + MF 15 10 7 144.8 16 11.1 [6.8, 18.0]
Trichomoniasis HIVRR 34 21 16 136.8 29 21.2 [14.7, 30.5]
HIVRR + MF 31 16 15 139.5 23 16.5 [11.0, 24.8]
Any STI HIVRR 53 29 23 130.3 41 31.5 [23.2, 42.8]
HIVRR + MF 44 27 21 130.3 39 29.9 [21.9, 41.0]
HIVRR, HIV risk reduction; HIVRR + MF, HIV risk reduction and microfinance.
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vaginal and/or anal intercourse with paying partners at the 6-
month assessment (IRR = 0.28, 95% CI = 0.08, 0.92) and a
10% greater reduction in the portion of income from sex work
at the 3-month assessment (b = 0.10, 95% CI = 0.17,
0.02) than participants in the HIVRR arm. In addition, results
show significant reductions in primary behavioural outcomes
for both arms at each follow-up compared to baseline. For
example HIVRR participants reported an 82% reduction at
three months (IRR = 0.18, 95% CI = 0.10, 0.31), an 85%
reduction at six months (IRR = 0.15, 95% CI = 0.08, 0.26),
and a 90% reduction at 12 months (IRR = 0.10, 95%
CI = 0.05, 0.19) in the number of acts of unprotected vaginal
and/or anal intercourse with all partners, compared to their
baseline assessment. Likewise, participants assigned to
HIVRR + MF reported a 92% reduction at three months
(IRR = 0.08, 95% CI = 0.04, 0.16), 88% reduction at
six months (IRR = 0.12, 95% CI = 0.07, 0.23), and a 91%
reduction at 12 months (IRR = 0.09, 95% CI = 0.04, 0.16) in
the number of acts of unprotected vaginal and/or anal
intercourse with all partners, compared to their baseline
assessment.
Table 5 presents the findings of multilevel models for sec-
ondary behavioural outcome measures. The findings show par-
ticipants assigned to HIVRR + MF had significantly greater
increase in financial self-efficacy at each follow-up (b = 1.59,
95% CI = 0.63, 2.55 at three months; b = 1.47, 95%
CI = 0.50, 2.43 at six months; and b = 1.31, 95% CI = 0.33,
2.28 at 12-months) than participants in the HIVRR arm.
Although there were no significant differences between arms
for other secondary behavioural outcomes, participants in
both arms reported significant reductions in the numbers of
all sex partners and paying partners, and significant increases
in financial self-efficacy, condom use self-efficacy, condom use
attitude, perceived social support, and access to care at the
follow-up compared to baseline assessment. Only
HIVRR + MF participants reported significant increases in
financial safety at the follow-up compared to baseline assess-
ment.
Table 3. Descriptive statistics for outcome variables at baseline and each follow-up assessment by study arm









Number of unprotected acts of vaginal and anal intercourse with
all partners: Mean (SD)
HIVRR 41.2 (69.8) 11.4 (23.0) 9.6 (18.8) 10.1 (29.0)
HIVRR + MF 36.6 (68.2) 7.9 (27.3) 9.0 (20.9) 7.0 (17.0)
Number of unprotected acts of vaginal and anal intercourse with
paying partners: Mean (SD)
HIVRR 20.3 (37.8) 2.5 (9.8) 1.2 (5.6) 0.4 (2.7)
HIVRR + MF 20.8 (48.8) 1.5 (10.3) 0.4 (2.1) 0.4 (3.1)
Injected drugs: # (%) HIVRR 60 (33.7%) 31 (19.1%) 28 (18.0%) 25 (16.5%)
HIVRR + MF 56 (32.0%) 26 (16.6%) 27 (17.3%) 17 (11.0%)
Unsafe injection: # (%) HIVRR 59 (33.2%) 31 (19.1%) 25 (16.3%) 24 (15.8%)
HIVRR + MF 52 (29.7%) 25 (15.9%) 25 (16.0%) 15 (9.7%)
Proportion of income from sex work: mean (SD) HIVRR 0.57 (0.33) 0.23 (0.31)* 0.17 (0.27) 0.11 (0.24)
HIVRR + MF 0.58 (0.36) 0.15 (0.25)* 0.13 (0.26) 0.11 (0.27)
Number of sex partners: mean (SD) HIVRR 19.0 (40.3) 2.4 (5.3) 1.8 (5.4) 0.8 (1.6)
HIVRR + MF 17.0 (47.7) 2.9 (13.6) 2.2 (14.8) 0.8 (3.5)
Number of paying partners: mean (SD) HIVRR 13.2 (31.1) 1.3 (3.8) 1.0 (4.7) 0.3 (1.1)
HIVRR + MF 12.2 (36.4) 1.4 (7.0) 1.5 (14.9) 0.4 (3.3)
Financial self-efficacy: mean (SD)a HIVRR 12.6 (4.0) 13.0 (4.1) 13.2 (4.4) 14.1 (3.9)
HIVRR + MF 11.8 (4.0) 13.8 (4.0) 13.9 (4.3) 14.7 (4.1)
Financial safety: mean (SD)b HIVRR 16.5 (3.1) 16.4 (2.8)* 16.6 (3.1) 16.4 (3.2)
HIVRR + MF 16.4 (3.1) 17.1 (2.4)* 16.6 (3.3) 17.0 (2.6)
Condom use self-efficacy: mean (SD)c HIVRR 19.7 (6.0) 23.7 (4.5) 23.4 (5.0) 23.0 (5.5)
HIVRR + MF 20.2 (5.9) 23.9 (3.6) 23.4 (5.0) 23.7 (4.4)
Condom use attitudes: mean (SD)d HIVRR 18.2 (5.2) 20.9 (5.9)* 21.4 (5.6) 22.0 (5.7)
HIVRR + MF 18.4 (5.5) 22.3 (6.2)* 22.6 (5.9) 22.6 (6.5)
Perceived social support: mean (SD)e HIVRR 44.4 (19.4) 49.9 (20.2)** 51.3 (21.2) 51.8 (23.3)*
HIVRR + MF 47.8 (19.6) 57.8 (19.4)** 55.7 (22.4) 57.6 (22.3)*
Access to care: mean (SD)f HIVRR 16.4 (3.9)** 17.7 (4.5)** 18.0 (4.3)** 18.2 (4.1)**
HIVRR + MF 17.8 (4.4)** 19.1 (4.4)** 19.5 (5.0)** 20.5 (4.7)**
HIVRR + MF, HIV risk reduction and microfinance; HIVRR, HIV risk reduction.
a
Financial Self-Efficacy: 4 items, 5-point Likert scale (1 = “Not at all confident” to 5 = “Extremely confident”);
b
financial Safety: 4 items, 5-point Lik-
ert scale (1 = “Very strongly disagree” to 5 = “Very strongly agree”);
c
condom Use Self-Efficacy: 9 items, 3-point Likert scale (1 = “Not at all confi-
dent” to 3 = “Very confident”);
d
condom Use Attitudes: 9 items, 5-point Likert scale (0 = “Strongly disagree” to 4 = “Strongly Agree”);
e
Social
Support (MSPSS): 12 items, 7-point Likert scale (1 = “Very strongly disagree” to 7 = “Very strongly agree”);
f
Access to Care: 6 items, 5-point Likert
scale (1 = “Strongly disagree”, 5 = “Strongly agree”); *p < 0.05, **p < 0.01 by 2-tailed t-test or Chi-squared test at the baseline or each follow-up
assessment



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The results show that both HIVRR control and HIVRR + MF
treatment participants significantly reduced sexual and drug
use risk behaviours at post-intervention assessments com-
pared to baseline, including numbers of commercial partners,
unprotected sex acts with all partners, and unsafe injections.
Both arms also showed improvements in financial outcomes,
including the proportion of their income from sex work, finan-
cial self-efficacy and safety, as well as on condom use attitudes
and self-efficacy, social support, and self-reported access to
medical care. Neither arm showed significant decreases in HIV
or STI incidence; this lack of support for biological STI out-
comes is consistent with other evidence-based interventions
[23,24].
Unlike other studies to-date there were very few differences
between the two study arms [12-15]. The HIVRR + MF arm
showed a significantly greater reduction in the number of
unprotected sex acts with paying partners than the HIVRR con-
trol arm at the 6-month follow up compared to the baseline,
but this difference was not sustained over the full follow-up per-
iod. Likewise, HIVRR + MF participants showed 10% greater
reduction in the proportion of income from sex work than
HIVRR participants at the 3-month assessment, but this differ-
ence was not sustained at other follow-up points. Only on finan-
cial self-efficacy did the HIVRR + MF arm show significantly
greater improved performance over the HIVRR arm. Therefore
it seems that the extra microfinance components received by
the HIVRR + MF treatment arm did not provide any measur-
able significant additional protection beyond the HIVRR alone.
There are several explanations for the lack of significant dif-
ference between study arms on most risk outcomes. First, we
consider whether the HIVRR intervention provided to both
arms was itself adequate in reducing risk behaviours. This
robust intervention had been carefully adapted and tailored to
the needs of FSW who use drugs in Kazakhstan through a
multi-step process, and both arms showed high retention, par-
ticipation, and engagement [17]. The high prevalence of STIs,
homelessness, and food insecurity at baseline suggests that
participants in both arms had diverse and acute unmet needs
prior to the intervention. Indeed, both arms reported signifi-
cantly increased access to care at all follow-ups, suggesting
that HIVRR alone removed many of the barriers to medical
and social services that drive these risks. Furthermore, partici-
pation in a cohort may have enhanced peer connections and
support in both arms, which may facilitate linkage to commu-
nity resources and reduction in risk behaviours [25-27]. The
increases in perceived social support for both arms necessi-
tate further exploration of the impact of FSW peer networks
on risk reduction.
Another explanation is that the MF intervention compo-
nents were not sufficient to overcome barriers to successful
transition to alternative employment. These may include envi-
ronmental barriers such as employment or job availability, eco-
nomic barriers such as the higher relative income from sex
work compared to alternative jobs, or persistent interpersonal
barriers such as stigma or drug use, impeding perceived or
real access to employment [28]. As noted elsewhere [17],
Kazakhstan underwent a recession in 2015 and 2016 that
may have impacted participants’ abilities to save money and to
find sustainable employment. Another barrier may be the
length of time needed to successfully transition to alternative
employment.
These unsustained, yet significant differences between arms
suggest the need to assess the differential impacts of various
microfinance components. Others have highlighted the impor-
tance of disentangling impacts of combination interventions
prior to further scale-up [29]. Additionally, we consider
whether additional employment-related environmental sup-
ports could enhance the microfinance components. For exam-
ple future microfinance programmes including vocational
training elements must work closely with NGOs and employ-
ment agencies to ensure alternative employment opportunities
exist for trained participants.
4.1 | Strengths and limitations
Our study utilized a convenience sample of FSW who used
drugs recruited from specific venues and through peer net-
works in two cities. This limits the generalizability of our find-
ings to FSW populations in other settings, both in Central
Asia and globally. There is also potential of participant
response bias, including social pressures to under-report num-
bers of sexual partners and risk behaviours. We mitigated this
risk by utilizing a private computer-assisted self-interview
process. Finally, because we utilized peer referral recruitment,
participants may have had friends or acquaintances in differ-
ent cohorts, and therefore contamination between study arms
is possible. However, given the complexity of MF intervention
components (e.g. specialized vocational skills), we do not
believe this had a large impact on outcomes.
5 | CONCLUSIONS
Findings suggest that there may be structural limitations to
the promise of microfinance for HIV risk reduction among
FSW who use drugs. Nova is one of the first studies among
this vulnerable and under-researched population, and its
acceptability and feasibility, described elsewhere [17], are
promising. However, further adaptation of the microfinance
elements, as well as broader policy changes that can expand
employment opportunities may be necessary to observe the
sustainable improved impact of microfinance. Given accumu-
lated knowledge regarding the structural barriers to risk
reduction, particularly in low and middle-income countries and
among this vulnerable population, we encourage continued
examination of the potential of microfinance for HIV risk
reduction.
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